174 related articles for article (PubMed ID: 30297283)
1. Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.
Boutin S; Roy J; Maltais R; Alata W; Calon F; Poirier D
Bioorg Med Chem Lett; 2018 Dec; 28(22):3554-3559. PubMed ID: 30297283
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency.
Boutin S; Maltais R; Roy J; Poirier D
Eur J Med Chem; 2021 Jan; 209():112909. PubMed ID: 33081987
[TBL] [Abstract][Full Text] [Related]
3. Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase.
He XY; Wegiel J; Yang SY
Brain Res; 2005 Apr; 1040(1-2):29-35. PubMed ID: 15804423
[TBL] [Abstract][Full Text] [Related]
4. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Bellavance E; Luu-The V; Poirier D
J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
[TBL] [Abstract][Full Text] [Related]
5. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
6. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders.
Yang SY; He XY; Isaacs C; Dobkin C; Miller D; Philipp M
J Steroid Biochem Mol Biol; 2014 Sep; 143():460-72. PubMed ID: 25007702
[TBL] [Abstract][Full Text] [Related]
7. Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.
Maltais R; Trottier A; Delhomme A; Barbeau X; Lagüe P; Poirier D
Eur J Med Chem; 2015 Mar; 93():470-80. PubMed ID: 25728028
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
[TBL] [Abstract][Full Text] [Related]
9. Novel Benzothiazole-based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer's Disease Treatment.
Aitken L; Benek O; McKelvie BE; Hughes RE; Hroch L; Schmidt M; Major LL; Vinklarova L; Kuca K; Smith TK; Musilek K; Gunn-Moore FJ
Molecules; 2019 Jul; 24(15):. PubMed ID: 31362457
[No Abstract] [Full Text] [Related]
10. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
11. C-3 Steroidal Hemiesters as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 10.
Hanzlova M; Slavikova B; Morozovova M; Musilek K; Rotterova A; Zemanová L; Kudova E
ACS Omega; 2024 Mar; 9(10):12116-12124. PubMed ID: 38496976
[TBL] [Abstract][Full Text] [Related]
12. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
13. Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation.
Benek O; Vaskova M; Miskerikova M; Schmidt M; Andrys R; Rotterova A; Skarka A; Hatlapatkova J; Karasova JZ; Medvecky M; Hroch L; Vinklarova L; Fisar Z; Hroudova J; Handl J; Capek J; Rousar T; Kobrlova T; Dolezal R; Soukup O; Aitken L; Gunn-Moore F; Musilek K
Eur J Med Chem; 2023 Oct; 258():115593. PubMed ID: 37390508
[TBL] [Abstract][Full Text] [Related]
14. Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase.
Yang SY; He XY; Schulz H
Trends Endocrinol Metab; 2005; 16(4):167-75. PubMed ID: 15860413
[TBL] [Abstract][Full Text] [Related]
15. Involvement of Type 10 17β-Hydroxysteroid Dehydrogenase in the Pathogenesis of Infantile Neurodegeneration and Alzheimer's Disease.
He XY; Frackowiak J; Dobkin C; Brown WT; Yang SY
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139430
[TBL] [Abstract][Full Text] [Related]
16. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
17. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
Owen CP; Ahmed S
Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
[TBL] [Abstract][Full Text] [Related]
18. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.
Poirier D
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):83-94. PubMed ID: 21182944
[TBL] [Abstract][Full Text] [Related]
19. Physiologically relevant fluorescent assay for identification of 17β-hydroxysteroid dehydrogenase type 10 inhibitors.
Schmidt M; Vaskova M; Rotterova A; Fiandova P; Miskerikova M; Zemanova L; Benek O; Musilek K
J Neurochem; 2023 Oct; 167(2):154-167. PubMed ID: 37458164
[TBL] [Abstract][Full Text] [Related]
20. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
Tremblay MR; Poirier D
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
